All In Biotech

Free tool

FAERS Monitor: Zyrtec-D 12 Hour

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021150 or its brand name (Zyrtec-D 12 Hour, Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

3,003

Serious

1,129

38% of reports

Hospitalization

516

Death reported

320

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective563
  • fatigue414
  • pain407
  • off label use389
  • rash361
  • abdominal discomfort339
  • alopecia335
  • rheumatoid arthritis331
  • pemphigus330
  • systemic lupus erythematosus320
  • product use issue306
  • maternal exposure during pregnancy304
  • glossodynia299
  • hand deformity294
  • swelling294

Reports by year received

View as table
YearReports
20051
200613
200735
20084
20103
20114
201227
201355
201448
2015293
2016348
2017289
2018140
2019157
2020189
2021175
2022227
2023271
2024258
2025300
2026165

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,156 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pemphigusSignal330189.9171.260,214
hand deformitySignal294160.6143.845,447
glossodyniaSignal29994.885.127,318
systemic lupus erythematosusSignal32063.757.419,546
maternal exposure during pregnancySignal30424.021.56,674
swellingSignal29422.119.85,900
rheumatoid arthritisSignal33120.518.56,128
abdominal discomfortSignal33914.212.84,165
alopeciaSignal33512.010.83,382
product use issueSignal30611.410.32,921
rashSignal3615.85.31,460
painSignal4074.64.21,194
fatigueSignal4143.73.4854
off label useSignal3893.12.8579
drug ineffectiveSignal5633.02.8795

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.